Drug-induced esophagitis

Abstract

Drug-induced esophagitis is being recognized increasingly in the past few years. Since 1970 more than 650 cases have been reported worldwide caused by 30 or more medications. We have reviewed these cases with a view to classifying this disease based on underlying pathological mechanism. Drug-induced esophageal injury tends to occur at the anatomical site of narrowing, with the middle third behind the left atrium predominating (75.6%). The disease is broadly classified into two groups. The first group being transient and self-limiting as exemplified by the tetracycline group induced injury (65.8%). The second is the persistent esophagitis group, often with stricture, with two distinct entities: (i) patients on nonsteroidal anti-inflammatory agents whose injury is aggravated by gastroesophageal reflux (21.8%) (reflux aggravated); and (ii) patients with potasium chloride and quinidine sulphate induced injury (12.4%) (persistent drug injury). Severe esophageal injury has been reported in some women taking biphosphonates as treatment for postmenopausal osteoporosis. Endoscopic findings in such patients with esophageal injury generally suggested a chemical esophagitis, with erosions or ulcerations and exudative inflammation accompanied by thickening of the esophageal wall. Most cases of medication-induced esophageal injury heal without intervention within a few days. Thus, the most important aspect of therapy is to make the correct diagnosis and then to avoid reinjury with the drug. When possible, potentially caustic oral medications should be discontinued.

Adverse effects of drugs on the esophagus

“…Drug-induced esophageal injury tends to occur at the anatomical site of narrowing, with the middle third behind the left atrium predominating (75.6%). [15] Esophageal biopsies are rarely helpful and show only acute inflammatory changes. However biopsies help to exclude chronic inflammatory diseases (i.e.…”

Contralateral Prophylactic Reinforcement in Case of First Low-Energy Hip Fracture: First-in-Man Clinical Data of a New Percutaneous Internal Fixation Device

“…Secondly, the efficiency of the medication treatments for osteoporosis is limited, especially because the patient's compliance is very low [7,8]. The adverse side effects of these treatments are often an obstacle to a long-term intake: Jaw necrosis, oesophageal and gastric complications, atypical fractures [9][10][11][12][13]. On the other hand some drug treatments are efficient to reduce the hip fracture rate only after 12 to 36 months of use [7].…”

Programa D-Valor: evaluación del servicio de dispensación de bifosfonatos

“…Hay que asegurar un paso rápido por el esófago minimizando el contacto del medicamento con las paredes del esófago (11), porque puede producir esofagitis (12,13). Por la misma razón hay que evitar el reflujo permaneciendo erguido.…”